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Pharmacological therapyVery-Long-Chain Acyl-CoA Dehydrogenase deﬁciency (VLCADD) is an autosomal recessive disorder
considered as one of the more common ß-oxidation defects, possibly associated with neonatal cardiomyo-
pathy, infantile hepatic coma, or adult-onset myopathy. Numerous gene missense mutations have been
described in these VLCADDphenotypes, but only few of themhave been structurally and functionally analyzed,
and the molecular basis of disease variability is still poorly understood. To address this question, we ﬁrst
analyzed fourteen disease-causing amino acid changes using the recently described crystal structure of VLCAD.
The predicted effects varied from the replacement of amino acid residues lining the substrate binding cavity,
involved in holoenzyme–FAD interactions or in enzyme dimerisation, predicted to have severe functional
consequences, up to amino acid substitutions outside key enzyme domains or lying on near enzyme surface,
with predicted milder consequences. These data were combined with functional analysis of residual fatty acid
oxidation (FAO) and VLCAD protein levels in patient cells harboring these mutations, before and after
pharmacological stimulation by bezaﬁbrate. Mutations identiﬁed as detrimental to the protein structure in the
3-D model were generally associated to profound FAO and VLCAD protein deﬁciencies in the patient cells,
however, some mutations affecting FAD binding or monomer–monomer interactions allowed a partial
response to bezaﬁbrate. On the other hand, bezaﬁbrate restored near-normal FAO rates in some mutations
predicted to have milder consequences on enzyme structure. Overall, combination of structural, biochemical,
and pharmacological analysis allowed assessment of the relative severity of individual mutations, with
possible applications for disease management and therapeutic approach.is Descartes, 45 rue des Saints-
ll rights reserved.© 2010 Elsevier B.V. All rights reserved.1. Introduction
Themitochondrial fatty acid ß-oxidation represents amajor source
of energy in a number of tissues including liver, heart, and skeletal
muscle, and, accordingly, genetic defects in thismetabolic pathway are
often associated with complex and severe clinical manifestations.
Very-Long-Chain-Acyl-CoA Dehydrogenase (VLCAD), one of the ﬁve
acyl-CoA dehydrogenases (ACAD) that catalyze the ﬁrst step of
mitochondrial fatty acid ß-oxidation (FAO), plays a prominent role
in the use of long-chain fatty acids as energy substrates in human [1].
VLCADdeﬁciency is an autosomal recessive disorder considered as one
of themore common FAO defect, with an estimated incidence of about1/31500 births [2]. It is characterized by three major phenotypes: a
generally fatal form with cardiomyopathy and hepatic failure in the
neonate, an intermediate infantile presentation with liver insufﬁcien-
cy, and a mild adolescent onset myopathic form [3]. In addition to
clinically ill patients, asymptomatic VLCAD-deﬁcient newborns have
nowbeen characterized, as a result of newborn screening programs for
this disorder [4].
Themolecular basis of VLCADdeﬁciency is complex,with about one
hundred mutations described [5]. Mutations of null type, which result
in complete loss of enzymatic function, are always associated to severe
disease presentation [3,6]. However, the majority of diagnosed
patients, and all asymptomatic newborns so far, harbor missense
mutations in the VLCAD gene. Despite marked progress in character-
ization of this disease, VLCAD deﬁciency is still considered as a
relatively insidious disease because of its variable phenotype, and
because of the lack of clear phenotype-genotype correlations for
missense mutations [2]. Functional analysis in various expression
systems can provide valuable data on the cellular effects and severity
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complex to be applied to the whole panel of missense mutations
presently known in this disease. In line with this, there is a direct
clinical need to deﬁne approaches for analysis of individual VLCAD
missense mutations, in order to improve management of diagnosed
patients and to aid the prognosis and treatment of VLCAD-deﬁcient
asymptomatic newborns [2].
To address this question, we evaluated an approach based on
combining predictive analysis of mutation effects in a 3-D VLCAD
model, and biochemical analysis of patient cells using relatively
widespreadmethods. The crystal structure of VLCADhas recently been
elucidated, and the 3-dimentional model shows that the enzyme
forms a homodimer associated with the inner mitochondrial mem-
brane, in contrast with the majority of ACADs, which are soluble
homotetrameric proteins [7]. The N-terminal domain of VLCAD
(∼400 amino acid residues) presents a high sequence identity and
homology with MCAD, and has the same polypeptide fold as the
soluble ACADs. On the other hand, the C-terminal domain composed
of about 180 residues is unique to VLCAD, and forms a helical bundle
that interacts with the N-terminal domain in a similar manner as the
dimer–dimer interaction in the tetrameric ACADs. In the C-terminal
domain, it is proposed that the fragment including residues 485 to
519, which is disordered in the crystal structure, forms an amphi-
pathic helix with six positively charged residues, responsible for
anchoring of VLCAD by interacting with negatively charged lipid
head groups in the inner mitochondrial membrane [7]. Glu462 is the
catalytic residue in VLCAD [8] and is conserved in several members
of ACAD family [9].
In our study, fourteen disease-causing amino acid substitutionswere
reported in the 3-D VLCADmodel, with the aim to predict their possible
deleterious effects on structure and function of the enzyme. In parallel,
biochemical studies of VLCAD protein levels and ß-oxidation ﬂux were
performed in patient cells harboring these mutations, before and after
treatment by bezaﬁbrate. Indeed,we recently showed that treatment by
bezaﬁbrate efﬁciently reveals maximal metabolic capacities in VLCAD-
deﬁcient patient cells, in contrast to basal measurements performed in
the absence of pharmacological stimulation [10]. We thus analyzed the
correlations between predictions of mutation severity from the 3-D
model, and residual FAO capacities and protein levels in patient cells,
allowing a comparative analysis of individual mutation effects in our
panel of missense mutations.Table 1
VLCAD patient genotypes and corresponding FAO ﬂux.
Groups Amino acid change Nucleotide change
Allele 1 Allele 2
Control
A G185S/N252_H293del42 c.553GNA IVS8-2ANC
A G222R/G222R c.664GNA c.664GNA
A R366H/R453X c.1097GNA c.1358GNT
A K382Q/E130fsX216 c.1144ANC c.388_391del4
A G441D/N252_H293del42 c.1322GNA IVS8-2ANC
A R453Q/R453Q c.1358GNA c.1358GNA
B N122D/N122D c.364ANG c.364ANG
B T260M/A640fsX679 c.779CNT c.1918_1921del4
B R286G/Q13X c.856ANG c.37CNT
C V174M/V174M c.520GNA c.520GNA
C A416T/K600fsX679 c.1246GNA c.1798delA
C/A A304T/G439D c.910GNA c.1316GNA
C/C D405H/R450H c.1213GNC c.1349GNA
A to C correspond to the predicted effects of disease-causing missense mutations from in si
monomer interactions, B: missense mutations inducing major tertiary structure re-arrangem
structural consequences.
The numbering of 1/ nucleotides starts at the ﬁrst adenine of the translation initiation codon
codon. FAO (Fatty Acid Oxidation) ﬂux was measured in nmol 3H FA/h/mg protein from d
NA: cells not available.2. Materials and methods
2.1. Patient ﬁbroblasts
VLCAD-deﬁcient human skin ﬁbroblasts used for this study have
been described previously [10]. Mutations and genotypes harbored in
these cell lines are mentioned in Table 1. Patients were either
homozygous for a missense mutation (N122D, V174M, G222R, or
R453Q), or carried amissensemutation (G185S, T260M, R286G, R366H,
K382Q, A416T, or G441D) associated to a null mutation on the other
allele, or were compound heterozygous for two missense mutations
(A304T/G439D or D405H/R450H). Fibroblasts were grown in standard
Ham-F10medium (Invitrogen, Cergy-Pontoise, France)with glutamine,
12% fetal bovine serum and 100 U/ml penicillin and 0.1 mg/ml
streptomycin under standard conditions, as previously described [11].
For treatment, cells were incubated in fresh media containing 400 µM
bezaﬁbrate (Sigma) or the equivalent amount of DMSO (vehicle, 0.05%)
for 48 h.
2.2. Fatty acid oxidation (FAO)
FAO ﬂux was determined by quantifying the production of 3H2O
from (9,10−3H) palmitate (Perkin Elmer), as previously described
[12]. Palmitate bound to fatty acid-free albumin was used at the ﬁnal
concentration of 125 μM (60 Ci/mmol). For each cell line, FAO
measurements were performed in triplicate, and repeated in two to
three independent experiments. The oxidation rates were expressed
as nmol of [3H] fatty acid oxidized per hour per mg of cell protein
(nmol [3H] FA h−1 mg−1 protein).
2.3. Western blot analysis
Control and VLCAD ﬁbroblasts were harvested in RIPA buffer
(50 mM Tris, pH 7.5, 150 mM NaCl, 1%NP40, 0.25% sodium deox-
ycholate, 0.1% SDS, 10 µg/ml leupeptin, 10 µg/ml aprotinin, and 1 mM
phenylmethylsulfonyl ﬂuoride) to prepare protein extracts. 20 µg of
total protein per lane were resolved by 10% SDS-PAGE and transferred
to Hybond-P PVDF membrane (Amersham Biosciences, Freiburg,
Germany). The following antibodies were used: rabbit polyclonal
anti-VLCAD (kindly provided by Dr S. Yamagushi, Japan), and mouse
monoclonal anti-actin (Chemicon International, Temecula, USA). TheFAO ﬂux Fold-increase
Non treated Treated FAO-ﬂux Protein level
4.8±1.0 7.6±0.35 1.6 2
0.24±0.02 0.41±0.05 1.7 7
0.46±0.02 0.81±0.09 1.8 5.6
0.71±0.1 1.85±0.3 2.6 10
0.60±0.17 2.27±0.33 3.8 9
0.26±0.15 0.50±0.37 1.9 7
0.24±0.01 0.23±0.01 1 NA
0.32±0.04 0.21±0.3 1 1
0.32±0.15 0.54±0.37 1.7 1
0.7±0.01 1.28±0.13 1.8 1
1.29±0.07 4.14±0.28 3.2 2.9
1.49±0.54 2.7±0.75 1.8 2.3
1.43±0.18 3.30±0.1 2.3 3
1.90±0.7 3.35±1 1.8 2.4
lico analysis. A: missense mutations affecting substrate- or FAD-binding, or monomer–
ents outside catalytic or dimerization domains, and C: missense mutations with minor
and 2/ amino acids starts at the ﬁrst methionine encoded by the translation initiation
eﬁcient patient ﬁbroblasts, before and after bezaﬁbrate treatment (400 µM, 48 h).
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respectively, and detected using horseradish peroxidase (HRP)
conjugated anti-rabbit or anti-mouse IgG, and the chemiluminescent
reagent, ECL (Amersham Biosciences, Freiburg, Germany). Immuno-
reactive bands corresponding to the two proteins were scanned by
densitometry with a computerized video densitometer.
2.4. In silico mutation analysis
Selected mutations were analyzed based on the recently deter-
mined structure of VLCAD [7]. Speciﬁc mutations were introduced to
the wild-type structure (PDB ID, 3B96) in silico using the model-
building program COOT [13]. When applicable, the most appropriate
rotamer was chosen to ﬁt the space and surrounding for the mutation
site, maximizing hydrogen bonding, ionic, and/or hydrophobic
interactions. The resulting structure was compared with the wild-
type for assessment of the protein integrity, including cofactor
binding, active site conﬁguration, and protein stability. All ﬁgures
were generated using the graphic program PyMOL [14]. The location
of analyzed mutations in the VLCAD 3-D structure is depicted in Fig. 1.
3. Results
The 3-D analysis revealed that six of the mutations considered in
our study, namely G185S, G222R, R366H, K382Q, G441D, and R453Q
could induce major structural alterations in substrate-binding, FAD-
binding, or in enzyme monomer–monomer interactions (Fig. 1). The
G185S mutation is predicted to affect the conformation of substrate
binding cavity. Indeed, the conserved Gly185 residue lies in a very
hydrophobic pocket surrounded by Ile176, Leu178, and Ile184, all of
which are lining the acyl-CoA binding cavity. Furthermore, homolog of
Ile184 in theMCAD (Leu103) or SCAD structure (Leu98) plays a role in
the fatty acyl moiety binding [15,16]. Accordingly, introduction of a
polar serine residue in position 185 (G185S) could directly affect the
substrate binding. The R453Q substitution is another example of
mutation thatmight affect substrate binding and catalysis, by inducing
changes in the positioning of catalytic glutamate (Glu462, see Fig. 2A).
Interestingly, mutation of the equivalent residue in the SCAD enzyme
(R359C) was also shown to be disease-causing in human, and cDNA
expression studies of this SCAD mutation suggested major protein
folding alterations leading to aggregation of the mutated protein [17].
Gly222 is the ﬁrst residue of a conserved Gly-Ser-Asp (GSD) segmentFig. 1. Ribbon diagram of the human VLCAD dimer (PDB 3B96) with various mutation sites
have CPK coloring with yellow carbons. Mutation sites are shown in only one subunit.located at the loop between strands 1 and 2 (see Fig. 3A), which was
shown to be directly involved in the binding of FAD in bothMCAD and
SCAD [15,16,18]. Detailed analysis of G222R mutation effects is
provided in Fig. 3A. Gly441 is also part of a highly conserved motif
(Gly-Gly-x-Gly) close to the FAD binding pocket [19]. Substitution of
Gly441 for aspartate could affect both FAD binding and monomer–
monomer interaction (see Fig. 3B). The conserved residue Arg366
participates to monomer–monomer interactions through making salt
bridgeswith the FAD pyrophosphate group of the neighboring subunit
(see Fig. 3C). When mutated to histidine (R366H), these salt bridges
would be replaced by hydrogen bonds, weakening FAD binding and
the association between enzyme monomers (see Fig. 3C). K382Q was
also predicted to affect FAD binding. Indeed, Lys382 located on helix H
makes a salt bridge with Glu432 on helix I (Fig. 3D). The K to Q
substitution would break this salt bridge and affect the position of
helix I, which could negatively affect FAD binding (Fig. 3D).
Fibroblasts harboring one of the aforementioned mutations (geno-
types G185S/N252_H293del42, G222R/G222R, R366H/R453X, K382Q/
E130fsX216 and G441D/N252_H293del42, R453Q/R453Q) exhibited a
marked FAO deﬁciency under basal conditions, with residual palmitate
oxidation rates ranging from0.24 to 0.71 nmol 3H. FA h−1mg−1 protein,
versus 4.8±1.0 nmol 3H. FA h−1mg−1 protein in control cells (i.e. 85 to
95% FAO deﬁciency in the patient cells) (Table 1). After treatment by
bezaﬁbrate, cells harboring G185S, G222R, or G441D exhibited quite
limited changes in FAO capacities, and therefore remained extremely
FAO-deﬁcient (0.41 to 0.81 nmol 3H. FA h−1 mg−1 protein) (Table 1). In
contrast, bezaﬁbrate induced a signiﬁcant FAO increase in cells
harboring R366H (from 0.71 to 1.85 nmol 3H. FA h−1 mg−1 protein)
or K382Q (from 0.6 to 2.27 nmol 3H. FA h−1 mg−1 protein) (Table 1).
Western-blot analysis revealed barely detectable VLCAD protein
levels in untreated cells harboring G185S, G222R, R366H, K382Q, or
G441D (Fig. 4). Exposure to bezaﬁbrate resulted in an induction of
VLCAD protein for G185S (7-fold), G222R (5.6-fold), and G441D (7-
fold), however the absolute levels remained considerably lower than
those found in control cells. On the other hand, residual VLCADprotein
was induced ten to nine-fold in patient cells harboring R366H or
K382Q in response to bezaﬁbrate, resulting in relatively high protein
levels compared to other missense mutations in this group.
3-D analysis also pointed to amino acid substitutions like T260M,
N122D, or R286G that do not directly affect catalytic enzyme domains,
but were predicted to disrupt local hydrogen bond networks and to
generate strong repulsive forces, leading to major tertiary structure. Each subunit is represented in gray or blue. Stick representations of the FAD cofactors
Fig. 2. Comparison of mild and severe VLCAD human mutation sites. Wild-type amino acid residues (magenta) are overlayed with the corresponding residues in the clinical variant
(cyan). Potential steric hindrances are depicted with red dashes. The cartoon carbon backbone representation is colored either grey or blue depending on the location of themutation
site in Fig. 1. A) The severe mutation R453Q would most certainly directly affect substrate binding and catalysis. The arginine to glutamine mutation would break a salt bridge
between residues Arg453 on helix J and Asp123 on helix A. The positioning of the catalytic glutamate (Glu462, not shown in the Figure), which is on a loop between helices J and K,
would likely be affected by the loss of this salt bridge. B) The severe clinical variant R286G is also not near FAD or substrate binding. However, the mutation would lead to the
breaking of hydrogen bonds with the main chain carbonyl oxygens of Glu253 and Ala256. This would lead to major tertiary structural rearrangement and protein instability. C)
V174M (mild) mutation site. No hydrogen bonds would be broken by this mutation. However, potential steric hindrances with Thr132 and Leu136 would lead to some structural
instability. D) The A304T (mild) mutation site also results potentially in only minor steric hindrance. The distal location of this mutation from FAD and substrate binding combined
with only slight structural perturbation result in a mild clinical phenotype.
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conserved Thr260 for a bulky hydrophobic methionine (T260M)
induces steric hindrance and disruption of the hydrogen bond normally
formed between Thr260 and the main chain amide nitrogen of Gly185.
Similarly, replacement of Asn122 by a negatively charged aspartate
(N122D) could disrupt hydrogen bonds formed between Asn122 and
three other residues, namely Asp171, Asn117, and Glu129, and also
cause strong charge repulsion among the three carboxylate groups of
these residues, predicted to induce severe protein instability. Finally,
R286G is another example of a severe variant targeting a residue outside
catalytic domains, leading to disrupt local hydrogen bonds (see Fig. 2B).
In keeping with structural analysis, FAO studies in cells carrying
N122D (N122D homozygous), or T260M (T260M/null), revealed very
low levels under basal conditions (0.32 nmol [3H]FA h−1 mg−1 protein,
i.e. FAO deﬁciency N93% compared to control cells), which did not vary in
response to bezaﬁbrate (Table 1). Fibroblasts harboring R286G/Q13X
showed slightly higher FAO rates, but remainedmarkedly deﬁcientwhen
treated by bezaﬁbrate. In parallel, western-blot studies revealed very low
protein levels in patient cells, which remained unchanged after treatment
by bezaﬁbrate (Fig. 4).
Two missense mutations, V174M and A416T, were predicted to have
relatively minor consequences. Indeed, V174M appears as a mild
mutation since introduction of a methionine would not break existinghydrogen bonds (see Fig. 2C). Patient ﬁbroblasts homozygous for V174M
exhibited FAO capacities equivalent to 27% of normal level (1.29 nmol 3H.
FA h−1 mg−1 protein) under basal conditions,whichmarkedly increased
after bezaﬁbrate treatment (4.14 nmol [3H]FA h−1 mg−1 protein, i.e. 86%
of normal level) (Table 1). A416T also appears as a mild mutation since
Ala416 is directly across from a phenylalanine on helix K, which forms a
loop around the catalytic Glu462, however, alanine substitution for a
threonine, with a slightly larger polar side chain, is predicted to induce
minor changes in the folding and positioning of helix K. Patient cells
harboring A416T exhibited palmitate oxidation rate reaching 31% of
control values under basal conditions (1.49 nmol [3H]FA h−1 mg−1 pro-
tein), and 56% (2.7 nmol [3H]FA h−1 mg−1 protein) after bezaﬁbrate
treatment (Table 1). Western-blot studies showed that cells carrying the
V174M or A416T mutation already exhibited signiﬁcant VLCAD protein
levels under basal conditions. These were clearly up-regulated (2.9- or
2.3-fold, respectively) in bezaﬁbrate-treated cells, resulting in VLCAD
protein levels close to those observed in control cells (Fig. 4).
We included in this study compound heterozygous genotypes
carrying two missense mutations, which could not be individually
analyzed on the basis of functional data. Thus, the genotype A304T/
G439D, which exhibited residual FAO close to 30% of control values
under basal conditions, raising to 65% after bezaﬁbrate treatment
(Table 1), might represent the association of two mild mutations or,
Fig. 3. Three dimensional dimeric structure of the VLCAD: ribbon diagram (PDB 3B96) withmutation sites. The twomonomers are colored gray and blue. Helices and beta-strands are
labeled as described [7] and those in the blue monomer are labeled with asterisks Stick representations of the FAD cofactors have CPK coloring with yellow carbons. The boxes
indicate mutation sites associated with FAD binding, whose vicinities are shown in greater detail in panels A-D. In each panel, amino acid residues that are mutated in patients are
shown with CPK coloring with magenta carbons and are labeled in magenta. Other neighboring residues depicted with CPK coloring grey carbons and labeled in black. Hydrogen
bonds and salt bridges are marked with dotted lines. A) G222R mutation site. Gly222 is located on the loop between beta-strands 1 and 2 close to the FAD phosphate, and the
substitution for a bulky charged arginine may change the loop conformation and disrupt binding of the cofactor, including a hydrogen bond between the FAD pyrophosphate and the
neighboring residue Ser223. B) G439D and G441D mutation sites are part of a conserved Gly-Gly-x-Gly motif on the loop between helices I and J of neighboring monomer in the
VLCAD dimeric molecule. Again, substitution of either Gly to an acidic residue would be detrimental to the interaction with the acidic pyrophosphate moiety of FAD in the
neighboring monomer, resulting in a weakening of the dimer interaction. C) R366H mutation site. Arg366 forms salt bridges with the FAD pyrophosphate of the other monomer.
Substitution of positively charged arginine 366 for a neutral histidine could lose this ionic interaction, instead forming a hydrogen bond between histidine 366 and the
pyrophosphate, weakening FAD binding and the association between enzyme monomers. D) K382Q mutation site. Lys382 on helix H forms a salt bridge with Glu432 on helix I, and
another salt bridge with Asp466 on helix K of the other monomer, which hydrogen bonds with the adenosine 2′-OH of the FAD. Since glutamine is almost isosteric as lysine, Gln382
can make hydrogen bonds with both Glu432 and Asp466, which are much weaker interactions compared to the salt bridges. The VLCAD catalytic glutamate (Glu462) is proximal to
the site of this salt bridge, and therefore the K382Q mutation may also affect its positioning.
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highly conserved Gly439 is involved in the same Gly-Gly-x-Gly motif
previously discussed in the case of the severe G441D mutation (see
Fig. 3B). In line with this, G439D substitution, which also led to the
substitutionof a small apolar glycine for a bulky charged aspartate, couldalter both FADbinding anddimer formation. Accordingly, the associated
A304T mutation is likely responsible for the expression of signiﬁcant
residual FAO ﬂux. In fact, in the 3-Dmodel, residueAla304 is located in a
hydrophobic region in the loop between strands 6 and 7 (see Fig. 2D),
and introduction of a hydrophilic threonine at this position would
Fig. 4. VLCAD protein levels in untreated (DMSO) or bezaﬁbrate-treated (BZ) patient ﬁbroblasts. Western-blot of protein extracts from patient or control cells were incubated with
anti-VLCAD antibody, and re-probed with anti-ß-actin antibody.
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structure.Western-blot analysis revealed relatively high VLCAD protein
levels in untreated A304T/G439D cells, increasing (3-fold) after
bezaﬁbrate treatment. In contrast, the genotype D405H/R450H most
likely associates two mild mutations. Indeed, previous studies using
transient expression in SV-40 ﬁbroblasts demonstrated that R450H is a
mild temperature-sensitive mutation [20]. Furthermore, modeling of
D405H showed that the conserved Asp405 is located on the surface of
the molecule and that substitution to a hydrophilic His would probably
have mild consequences on protein structure and stability. In this
genotype, FAO levels were signiﬁcantly increased after bezaﬁbrate
treatment. VLCAD protein abundance was clearly lower than normal in
the D405H/R450H genotype under basal conditions, but protein levels
increased 2.4 fold in response to bezaﬁbrate.
4. Discussion
Progress in the diagnosis of VLCAD deﬁciency led to the identiﬁca-
tion of a large number of disease-causing missense mutations, and
raised the question of elucidation of themolecular and cellular effects of
these various mutations. In our study, we used the recently published
crystal structureofVLCADtoperform3-Dmappingof fourteenmissense
mutations, in order to analyze their potential deleterious effects on
architecture of the active site, enzyme-cofactor interaction, enzyme
dimerisation, or folding of polypeptide chain. One of our objectives was
to evaluate the level of correlation between information gathered from
3-D analysis and biochemical data obtained frompatient cells harboring
these mutations. Six of the mutations studied (G185S, G222R, R366H,
K382Q, G441D, and R453Q) were predicted to induce major conforma-
tional changes in enzyme domains structurally essential for catalysis.
Fibroblasts harboring one of the three glycine substitutions (G185S,
G222R, G441D) all exhibited barely detectable FAO levels and were
unresponsive to bezaﬁbrate, in good correlation with the 3-D mapping
conclusions. Patient cells with the K382Q or R366Hmutations exhibited
detectable FAO ﬂux after bezaﬁbrate treatment, though much lower
than normal values. Interestingly, structural analysis predicted that
K382Q or R366Hmutations led to substitute salt bridge interactions by
hydrogen bonds, consistent with lesser consequences on enzyme
structure and stability. In contrast, substitutions of glycine residues
lead to disrupt existing bonds with the FAD group, and to create strong
repulsive forces, and, accordingly, are predicted to induce loss-of-
function and protein misfolding, especially if the amino acid is buried
deep inside the normal structure. Misfolded proteins due to severe
missense mutations are often degraded by the cellular protein quality
system [5], resulting in virtually no immunodetectable enzyme in the
patient cells. Consistent with this, missense mutations predicted to
induce major structural rearrangements (groups A and B) were all
associated to drastically reduced VLCAD protein levels under standard
conditions. Interestingly, mutant protein levels were found up-regulatedbybezaﬁbrate for someof these severemutations, particularly
in the case of R366H and K382Q, and this was associated with relatively
high FAO levels in drug-treated cells, compared to other severe
mutations.
The other eight mutations considered in our study did not affect
residues lying in enzyme domains essential for catalysis or monomer–
monomer association. More detailed analysis in the 3-D model
predicted that three of them could alter local bonding networks by
abolishing one (T260M), two (R286G), or three (N122D) hydrogen
bonds with nearby amino acids, in addition to causing steric hindrance
and strong charge repulsion. Altogether, 3-D analysis clearly supports
the hypothesis that these mutations could induce major protein
instability. Consistent with this, cells harboring N122D, T260M, or
R286 G showed extremely low residual VLCAD protein levels and were
found severely FAO-deﬁcient, whether or not treated by bezaﬁbrate.
Analysis of four other missense mutations (V174M, A304T, D405H,
A416T) pointed to residues that were not engaged in charge-charge
interactions or hydrogen bonding networks with other amino acids in
the 3-D structure of the enzyme. This is illustrated by V174M or A416T,
involving residues that take part to hydrophobic interactions outside
key domains, or near the surface, of the protein. Accordingly, these
mutations can be predicted to have relatively milder structural conse-
quences on protein folding. In linewith this, ﬁbroblasts carrying V174M
or A416T exhibited signiﬁcant amounts of protein and FAO levels at the
basal state, which were markedly increased in response to bezaﬁbrate.
In the case ofV174M, the high residual protein and FAO capacitiesmight
also be due to the fact that this patient cell line carries two V174M
alleles, whereas most other cell lines harbor one missense mutation
associated to a null allele.
Altogether, this study shows that analysis of individualmutations by
3-D mapping in the enzyme crystal structure can provide initial
indications on mutation effects that appear consistent with functional
data obtained from patient cells. Although structural analysis can
obviously not predict the importance of all interactions involved in the
mature protein, our data suggest that 3-D mapping can help to
distinguish between mutations that are likely to severely affect key
structural elements of the enzyme, thereby inducing complete loss-of-
function, and other types ofmutations targeting non-critical domains or
non-critical interaction networks, withmilder functional impact. On the
other hand, the fatty acid oxidation assay,which can easily be applied to
serial studies of patient cells, provides a valuable tool for analysis of
biochemical phenotypewhenpredictionsofmutation severity couldnot
be ﬁrmly established by in silico analysis. In addition, this study further
illustrates the potential of FAOmeasurements to evaluate the response
to bezaﬁbrate in various genotypes, and the correlation between
mutation severity and drug-induced changes in FAO in the patient
cells [10].
Our results are in good agreement with the literature data on
analysis of T260M, K382Q, and A416T, which are the only missense
484 S. Gobin-Limballe et al. / Biochimica et Biophysica Acta 1802 (2010) 478–484mutations previously analyzed in functional studies, among the panel
included in our study. In particular, these published data showed that
expression of cDNA encoding K382Q or A416T resulted in signiﬁcant
residual enzyme activity [21,22], whereas very low levels were
observed in the case of T260M [23]. It is worth mentioning that
combination of structural, biochemical and pharmacological analysis,
as performed in the present study, allowed not only to analyze the
relative severity of individual missense mutations, but also to assess
the capacity of patient cells to up-regulate their FAO capacity under
bezaﬁbrate stimulation. This approach could therefore bring relevant
information to aid prognosis and to consider therapeutic options in
clinically affected or asymptomatic individuals.
Finally, analysis of structural consequences of missense mutations
could also be helpful to provide rationale for the research of new
treatments. For example, it can be proposed that riboﬂavin supplemen-
tationmight further improve VLCAD residual enzyme activity in the case
of mutations affecting the FAD binding, but which do not fully abolish
residual FAO, such as R366H or K382Q. In line with this, it has been
recently reported that pharmacological doses of riboﬂavin could improve
patient condition in the mitochondrial electron transfer ﬂavoprotein-
ubiquinone oxidoreductase (ETF-QO) deﬁciency, suggesting that in-
creased FAD supply to the mitochondria might reduce the impact of
mutations affecting its binding [24,25]. Additionally, therapeutic
approaches based on chaperones, already tested in other genetic diseases
[26], could be relevant in the case of VLCADmissensemutationswhich do
not irreversibly affect the expression ofmutated enzyme (R366H, K382Q,
V174M, A416T). Accordingly, analysis of the consequences of the
mutations at the structural and biochemical level could therefore provide
important clues not only to improve patientmanagement, but also for the
research of future treatments.
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